BRPI0412493A - métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio - Google Patents

métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio

Info

Publication number
BRPI0412493A
BRPI0412493A BRPI0412493-6A BRPI0412493A BRPI0412493A BR PI0412493 A BRPI0412493 A BR PI0412493A BR PI0412493 A BRPI0412493 A BR PI0412493A BR PI0412493 A BRPI0412493 A BR PI0412493A
Authority
BR
Brazil
Prior art keywords
contraceptive
treatment methods
hormonal treatment
contraceptive regimens
estrogen administration
Prior art date
Application number
BRPI0412493-6A
Other languages
English (en)
Inventor
Robert G Bell
Carole S Ben-Maimon
Beata Iskold
Lance J Bronnenkant
Howard Hait
Kathleen Z Reape
Original Assignee
Duramed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duramed Pharmaceuticals Inc filed Critical Duramed Pharmaceuticals Inc
Publication of BRPI0412493A publication Critical patent/BRPI0412493A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODOS DE TRATAMENTO HORMONAL UTILIZANDO REGIMES CONTRACEPTIVOS COM ADMINISTRAçãO CONTìNUA DE ESTROGêNIO". A presente invenção fornece regimes contraceptivos nos quais é administrada a uma mulher uma forma de dosagem combinada de estrogênio e progestina seguido por um período de administração de estrogênio. Os regimes contraceptivos apresentados podem ser administrados a uma mulher como um método de fornecimento de benefícios não contraceptivos.
BRPI0412493-6A 2003-07-16 2004-07-16 métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio BRPI0412493A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48725703P 2003-07-16 2003-07-16
PCT/US2004/022829 WO2005007112A2 (en) 2003-07-16 2004-07-16 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration

Publications (1)

Publication Number Publication Date
BRPI0412493A true BRPI0412493A (pt) 2006-10-17

Family

ID=34079360

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412493-6A BRPI0412493A (pt) 2003-07-16 2004-07-16 métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio

Country Status (12)

Country Link
US (2) US7855190B2 (pt)
EP (1) EP1648382A4 (pt)
JP (2) JP2007534622A (pt)
CN (1) CN101001631B (pt)
AU (2) AU2004257772B2 (pt)
BR (1) BRPI0412493A (pt)
CA (2) CA2771944A1 (pt)
IL (1) IL172959A0 (pt)
NZ (3) NZ545130A (pt)
RU (2) RU2403046C2 (pt)
WO (1) WO2005007112A2 (pt)
ZA (1) ZA200600201B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
RU2351339C2 (ru) * 2001-12-05 2009-04-10 Дюрамед Фармасьютикалс, Инк. Оральные контрацептивы для предотвращения беременности и уменьшения предменструальной симптоматики
US20090163454A1 (en) * 2003-05-02 2009-06-25 Duramed Pharmaceuticals, Inc. Methods of Step-Down Hormone Treatment
AU2004257772B2 (en) * 2003-07-16 2009-12-17 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US7556150B2 (en) * 2004-06-07 2009-07-07 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of DUB
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2392332A1 (en) * 2004-10-07 2011-12-07 Teva Women's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
TW200726473A (en) * 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US7552098B1 (en) * 2005-12-30 2009-06-23 At&T Corporation Methods to distribute multi-class classification learning on several processors
CA2637608A1 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
US20090247493A1 (en) * 2006-01-27 2009-10-01 Duramed Pharmaceuticals, Inc. Regimens for Treatment of Conditions Related to Estrogen Deficiency
MX2008011074A (es) * 2006-03-02 2008-09-10 Warner Chilcott Co Inc Metodo anticonceptivo oral multifasico de ciclo prolongado.
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
AU2007256718A1 (en) * 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
WO2008018872A1 (en) * 2006-08-10 2008-02-14 Drugtech Corporation Therapeutic methods of using estrogen compositions
EP2164498A4 (en) 2007-06-04 2010-09-08 Univ California PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
CA2740002C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
EP3137088B1 (en) * 2014-04-28 2023-08-30 The Regents of The University of California Pharmaceutical packaging for estriol therapy for the treatment of multiple sclerosis
WO2015168000A1 (en) 2014-04-28 2015-11-05 The Regents Of The University Of California Estrogen combination for treatment of multiple sclerosis
WO2016036719A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
WO2016053946A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions and methods for maintaining cognitive function
US10467382B2 (en) * 2014-11-14 2019-11-05 Brazen Incorporated Conceivable basal body temperatures and menstrual cycle
EP3277285B1 (en) 2015-03-30 2024-07-17 The Regents of the University of California Estriol for reducing cortical gray matter atrophy
CN110740713A (zh) * 2017-03-15 2020-01-31 敏捷治疗公司 个性化避孕制剂
JP2022527411A (ja) * 2019-03-29 2022-06-01 マーテル，ブリジット セグメント化されたｅｖａ膣内リング
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US758605A (en) * 1902-04-14 1904-04-26 Joseph R Place Mechanism for securing rubber tires to fellies.
US3568828A (en) 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
DE2412775A1 (de) * 1974-03-16 1975-09-18 Interatom Absorberelement fuer kugelhaufenreaktoren
US4171358A (en) 1974-04-19 1979-10-16 Eli Lilly And Company Novel contraceptive method
US4145416A (en) 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
US4292315A (en) 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4215691A (en) 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4291014A (en) 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4438139A (en) 1979-08-14 1984-03-20 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estrogens
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
USRE35724E (en) 1982-04-28 1998-02-03 Bio-Technology General Corp. Contraception system and method
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4554554A (en) * 1983-09-02 1985-11-19 The United States Of America As Represented By The Secretary Of The Navy Quadrifilar helix antenna tuning using pin diodes
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4736849A (en) 1983-12-19 1988-04-12 Leonard Walter G Calendar-oriented pill dispenser
US4534468A (en) 1983-12-19 1985-08-13 Nuckols Walter S Calendar-oriented pill dispenser
JPS60174716A (ja) 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US5010070A (en) 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US4752478A (en) 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
US5296230A (en) 1985-02-25 1994-03-22 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US5208225A (en) 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US5108995A (en) 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5276022A (en) 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US5256421A (en) 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US4971998A (en) 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
CA1336328C (en) 1988-04-11 1995-07-18 Walter G. Leonard Method of increasing bone density in humans
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5098714A (en) 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (pt) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
DE4224534A1 (de) * 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19513662A1 (de) 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
FR2737411B1 (fr) 1995-08-01 1997-10-17 Theramex Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
DE19531936A1 (de) 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
US5747480A (en) 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US6139873A (en) 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
WO1998004267A1 (en) 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
WO1998004266A1 (en) 1996-07-26 1998-02-05 American Home Products Corporation Oral contraceptive
AU3888597A (en) 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
US5858405A (en) 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19705229C2 (de) 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
AU9028098A (en) * 1997-08-27 1999-03-16 Ortho Pharmaceutical Corporation Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
DE60041464D1 (de) * 1999-09-29 2009-03-12 Ibiden Co Ltd Wabenförmiger Filter und Anordnung von keramischen Filtern
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20010044431A1 (en) 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US7297688B2 (en) * 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
JP2004502729A (ja) 2000-07-06 2004-01-29 ワイス Ｓｓｒｉおよびエストロゲン剤の組み合わせ
AU2002309919B2 (en) 2001-05-16 2008-04-10 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
RU2351339C2 (ru) 2001-12-05 2009-04-10 Дюрамед Фармасьютикалс, Инк. Оральные контрацептивы для предотвращения беременности и уменьшения предменструальной симптоматики
US20040142914A1 (en) 2002-03-11 2004-07-22 Friedman Andrew Joseph Extended transdermal contraceptive regimens
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
ATE336252T1 (de) 2002-03-11 2006-09-15 Janssen Pharmaceutica Nv Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie
MXPA04009671A (es) 2002-04-03 2005-01-25 Barr Lab Inc Terapia de reduccion escalonada con estrogenos.
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040251301A1 (en) 2003-05-05 2004-12-16 Niemann Amy C. Device for calculating anticipated days for menstruation
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
AU2004257772B2 (en) * 2003-07-16 2009-12-17 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
KR101153527B1 (ko) 2003-09-04 2012-06-11 파마디자인 인코포레이티드 알약 저장 및 분배를 위한 알약 수용 슬리브를 갖는 케이스
EP1673094A1 (en) 2003-10-01 2006-06-28 Janssen Pharmaceutica N.V. Extended triphasic contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2392332A1 (en) 2004-10-07 2011-12-07 Teva Women's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20090247493A1 (en) * 2006-01-27 2009-10-01 Duramed Pharmaceuticals, Inc. Regimens for Treatment of Conditions Related to Estrogen Deficiency

Also Published As

Publication number Publication date
NZ585546A (en) 2011-10-28
AU2010201022A1 (en) 2010-04-08
JP2007534622A (ja) 2007-11-29
AU2004257772A1 (en) 2005-01-27
ZA200600201B (en) 2008-07-30
RU2006101214A (ru) 2007-08-27
CN101001631B (zh) 2014-08-06
CA2771944A1 (en) 2005-01-27
EP1648382A2 (en) 2006-04-26
EP1648382A4 (en) 2009-09-16
AU2010201022C1 (en) 2013-05-16
IL172959A0 (en) 2006-06-11
JP2011157389A (ja) 2011-08-18
RU2010118424A (ru) 2011-11-20
CA2532089C (en) 2012-05-22
AU2010201022B2 (en) 2012-09-27
WO2005007112A2 (en) 2005-01-27
NZ574964A (en) 2011-10-28
US20110124611A1 (en) 2011-05-26
NZ545130A (en) 2009-03-31
CA2532089A1 (en) 2005-01-27
WO2005007112A3 (en) 2007-01-18
US20050143359A1 (en) 2005-06-30
US7855190B2 (en) 2010-12-21
CN101001631A (zh) 2007-07-18
AU2004257772B2 (en) 2009-12-17
RU2403046C2 (ru) 2010-11-10

Similar Documents

Publication Publication Date Title
BRPI0412493A (pt) métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
WO2004098517A8 (en) Methods of hormonal treatment utilizing extended cycle contraceptive regimens
CO4970819A1 (es) Tratamiento de disfuncion sexual femenina en una hembra humana
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
EA200401355A1 (ru) Применение циклопамина при лечении псориаза и других кожных заболеваний
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
NO20060200L (no) Farmasoytisk formulering for prevensjons- og hormonerstatningsterapier
BRPI0411451A (pt) formas de dosagens orais de memantina
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
YU30002A (sh) Upotreba dipiridamola ili mopidamola u pripremanju leka za lečenje i prevenciju mikrocirkulacionih poremećaja koji zavise od fibrina
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
BRPI0516247A (pt) métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente
ATE516366T1 (de) Regulierte aptamer-therapeutika
EP1781277A4 (en) COMBINATION PREPARATION
RU2007138867A (ru) Режимы дозирования транс-кломифена
MA30665B1 (fr) Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee.
CY1111406T1 (el) Χρηση βαλερικης οιστραδιολης ή οιστραδιολης σε συνδυασμο με διενογεστη για την απο του στοματος θεραπεια της αιμορραγιας λογω δυσλειτουργιας της μητρας με τη μορφη απο του στοματος αντισυλληψης
CR8010A (es) Regimenes de contraceptivos transdermicos extendidos
NZ325874A (en) Combination injection preparation
JP2005532336A5 (pt)
CN104490512A (zh) 一种治疗性冷淡和性心理障碍的避孕套
CN204446253U (zh) 一种治疗性冷淡和性心理障碍的避孕套

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: DURAMED PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080073262/SP DE 27/11/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 47 DIAS PARA CUMPRIMENTO DE EXIGENCIA, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B25D Requested change of name of applicant approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: NOME ALTERADO DE: DURAMED PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 018110020180/SP DE 30/05/2011.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.